Apellis Pharmaceuticals finalized plans for a phase 3 clinical trial program for APL-2, its treatment for geographic atrophy associated with age-related macular degeneration, the company announced in a press release.
The program, set to begin in the second half of this year, will include two identical 600-patient prospective, multicenter, randomized, double-masked, sham-injection controlled studies evaluating the efficacy and safety of multiple intravitreal injections of the treatment, the release said.
APL-2 is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds
Uncategorized